<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02482857</url>
  </required_header>
  <id_info>
    <org_study_id>ASA-dos</org_study_id>
    <nct_id>NCT02482857</nct_id>
  </id_info>
  <brief_title>Optimal Dose of Acetylsalicylic Acid After Coronary Artery Bypass Grafting</brief_title>
  <official_title>Optimal Dose of Acetylsalicylic Acid After Coronary Artery Bypass Grafting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, open-label, randomized controlled trial. Patients with stable angina
      pectoris without use of dual antiplatelet therapy or anticoagulation therapy scheduled for
      coronary artery bypass grafting (CABG) at Karolinska University Hospital in Stockholm, Sweden
      will be eligible.

      This study investigates in patients having undergone CABG whether increasing the dose or the
      frequency of acetylsalicylic acid (ASA) treatment improves the efficacy of ASA regarding
      platelet inhibition compared to the standard dosing for cardiovascular prevention (75 mg once
      daily) in the first three months after surgery. Patients will be randomly assigned to
      postoperative ASA dose 75mg once daily, 75mg twice daily or 160 mg once daily. The study dose
      ASA will be started at hospital discharge and continued of three months. Blood samples for
      serum thromboxane B2 (TxB2) and other analyses will be taken before surgery, before
      discharge, and after one and three months. All available data will be collected
      prospectively. Informed consent will be obtained from patients meeting the inclusion criteria
      before the initiation of any study-specific procedures.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum thromboxane B2</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Multiple electrode aggregometry platelet aggregation</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Coronary Artery Bypass Surgery</condition>
  <condition>Stable Angina</condition>
  <arm_group>
    <arm_group_label>Acetylsalicylic acid 75 mg twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin 75 mg BID is a new experimental dosing regimen which has shown improved efficiency regarding laboratory parameters in several studies, mainly in diabetic patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acetylsalicylic acid 160 mg once daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin 160 mg OD is an accepted and used dosage after CABG.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acetylsalicylic acid 75 mg once daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin 75 mg OD is an accepted and used dosage after CABG.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylsalicylic acid</intervention_name>
    <description>To compare BID dosing with OD dosing with clinically used aspirin dosages.</description>
    <arm_group_label>Acetylsalicylic acid 75 mg twice daily</arm_group_label>
    <arm_group_label>Acetylsalicylic acid 160 mg once daily</arm_group_label>
    <arm_group_label>Acetylsalicylic acid 75 mg once daily</arm_group_label>
    <other_name>Aspirin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stable coronary artery disease

          -  ≥18 years of age

          -  Scheduled to undergo elective CABG surgery

          -  Willing to participate and able to provide informed consent

        Exclusion Criteria:

          -  Intake of drugs other than ASA that are known to influence platelet function,
             including nonsteroidal anti-inflammatory drugs (NSAIDs, including COX-2 selective
             anti-inflammatory drugs), GPIIbIIIa inhibitors, clopidogrel, dipyridamole, warfarin or
             acenocoumarol within 7 days of enrolment

          -  Hemorrhagic diathesis or known platelet dysfunction

          -  Chronic renal failure requiring dialysis

          -  Platelet count outside the 100 000 to 450 000/μL range

          -  Haemoglobin &lt; 8g/dl
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Hjemdahl, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska University Hospital</affiliation>
  </overall_official>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2015</study_first_submitted>
  <study_first_submitted_qc>June 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2015</study_first_posted>
  <last_update_submitted>March 6, 2018</last_update_submitted>
  <last_update_submitted_qc>March 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Magnus Dalén</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina, Stable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

